Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer

Steven M. Keller, Mark G. Vangel, Henry Wagner, Joan Schiller, Arnold Herskovic, Ritsuko Komaki, Robert Gray, Randolph Stuart Marks, Michael C. Perry, Robert B. Livingston, David H. Johnson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The occurrence of second primary tumors (SPTs) following adjuvant therapy for resected stages II and IIIa non-small cell lung cancer (NSCLC) was investigated. Data regarding SPTs were prospectively collected in all patients accrued to Eastern Cooperative Group Oncology E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC). Four hundred eighty-eight patients were accrued to the study, 242 to the RT arm and 246 to the CRT arm. Median follow-up was 73 months. Thirty patients (6.1%) developed 33 SPTs, 20 in the RT arm and ten in the CRT arm. Ten SPTs occurred within the upper aerodigestive tract, six in the RT arm and four in the CRT arm. Twenty-three SPTs occurred in other organs, 17 in the RT arm and six in the CRT arm. Median time to detection of a SPT for those patients randomized to RT and CRT was 43 and 36 months, respectively. The incidence of SPTs was 1.8% per patient-year of follow-up. Excluding skin tumors, the relative risk of death following diagnosis of a SPT for patients randomized to the CRT arm as compared with those randomized to RT alone was 2.26 (95% confidence interval, 0.78-5.58, P=0.12). Patients are at risk for developing a SPT following resection of stages II and IIIa NSCLC. The majority of SPTs occur outside the aerodigestive tract. Following development of a non-skin SPT, the survival difference between patients who had received adjuvant CRT and those treated with adjuvant RT alone was not significant.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalLung Cancer
Volume42
Issue number1
DOIs
StatePublished - Oct 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Therapeutics
Confidence Intervals
Skin
Survival

Keywords

  • Adjuvant therapy
  • Non-small cell lung cancer
  • Resectable
  • Second primary tumors

ASJC Scopus subject areas

  • Oncology

Cite this

Keller, S. M., Vangel, M. G., Wagner, H., Schiller, J., Herskovic, A., Komaki, R., ... Johnson, D. H. (2003). Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer, 42(1), 79-86. https://doi.org/10.1016/S0169-5002(03)00274-5

Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. / Keller, Steven M.; Vangel, Mark G.; Wagner, Henry; Schiller, Joan; Herskovic, Arnold; Komaki, Ritsuko; Gray, Robert; Marks, Randolph Stuart; Perry, Michael C.; Livingston, Robert B.; Johnson, David H.

In: Lung Cancer, Vol. 42, No. 1, 01.10.2003, p. 79-86.

Research output: Contribution to journalArticle

Keller, SM, Vangel, MG, Wagner, H, Schiller, J, Herskovic, A, Komaki, R, Gray, R, Marks, RS, Perry, MC, Livingston, RB & Johnson, DH 2003, 'Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer', Lung Cancer, vol. 42, no. 1, pp. 79-86. https://doi.org/10.1016/S0169-5002(03)00274-5
Keller, Steven M. ; Vangel, Mark G. ; Wagner, Henry ; Schiller, Joan ; Herskovic, Arnold ; Komaki, Ritsuko ; Gray, Robert ; Marks, Randolph Stuart ; Perry, Michael C. ; Livingston, Robert B. ; Johnson, David H. / Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. In: Lung Cancer. 2003 ; Vol. 42, No. 1. pp. 79-86.
@article{3d12b54cd99841dfb0d88586e7c765c3,
title = "Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer",
abstract = "The occurrence of second primary tumors (SPTs) following adjuvant therapy for resected stages II and IIIa non-small cell lung cancer (NSCLC) was investigated. Data regarding SPTs were prospectively collected in all patients accrued to Eastern Cooperative Group Oncology E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC). Four hundred eighty-eight patients were accrued to the study, 242 to the RT arm and 246 to the CRT arm. Median follow-up was 73 months. Thirty patients (6.1{\%}) developed 33 SPTs, 20 in the RT arm and ten in the CRT arm. Ten SPTs occurred within the upper aerodigestive tract, six in the RT arm and four in the CRT arm. Twenty-three SPTs occurred in other organs, 17 in the RT arm and six in the CRT arm. Median time to detection of a SPT for those patients randomized to RT and CRT was 43 and 36 months, respectively. The incidence of SPTs was 1.8{\%} per patient-year of follow-up. Excluding skin tumors, the relative risk of death following diagnosis of a SPT for patients randomized to the CRT arm as compared with those randomized to RT alone was 2.26 (95{\%} confidence interval, 0.78-5.58, P=0.12). Patients are at risk for developing a SPT following resection of stages II and IIIa NSCLC. The majority of SPTs occur outside the aerodigestive tract. Following development of a non-skin SPT, the survival difference between patients who had received adjuvant CRT and those treated with adjuvant RT alone was not significant.",
keywords = "Adjuvant therapy, Non-small cell lung cancer, Resectable, Second primary tumors",
author = "Keller, {Steven M.} and Vangel, {Mark G.} and Henry Wagner and Joan Schiller and Arnold Herskovic and Ritsuko Komaki and Robert Gray and Marks, {Randolph Stuart} and Perry, {Michael C.} and Livingston, {Robert B.} and Johnson, {David H.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0169-5002(03)00274-5",
language = "English (US)",
volume = "42",
pages = "79--86",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer

AU - Keller, Steven M.

AU - Vangel, Mark G.

AU - Wagner, Henry

AU - Schiller, Joan

AU - Herskovic, Arnold

AU - Komaki, Ritsuko

AU - Gray, Robert

AU - Marks, Randolph Stuart

AU - Perry, Michael C.

AU - Livingston, Robert B.

AU - Johnson, David H.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - The occurrence of second primary tumors (SPTs) following adjuvant therapy for resected stages II and IIIa non-small cell lung cancer (NSCLC) was investigated. Data regarding SPTs were prospectively collected in all patients accrued to Eastern Cooperative Group Oncology E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC). Four hundred eighty-eight patients were accrued to the study, 242 to the RT arm and 246 to the CRT arm. Median follow-up was 73 months. Thirty patients (6.1%) developed 33 SPTs, 20 in the RT arm and ten in the CRT arm. Ten SPTs occurred within the upper aerodigestive tract, six in the RT arm and four in the CRT arm. Twenty-three SPTs occurred in other organs, 17 in the RT arm and six in the CRT arm. Median time to detection of a SPT for those patients randomized to RT and CRT was 43 and 36 months, respectively. The incidence of SPTs was 1.8% per patient-year of follow-up. Excluding skin tumors, the relative risk of death following diagnosis of a SPT for patients randomized to the CRT arm as compared with those randomized to RT alone was 2.26 (95% confidence interval, 0.78-5.58, P=0.12). Patients are at risk for developing a SPT following resection of stages II and IIIa NSCLC. The majority of SPTs occur outside the aerodigestive tract. Following development of a non-skin SPT, the survival difference between patients who had received adjuvant CRT and those treated with adjuvant RT alone was not significant.

AB - The occurrence of second primary tumors (SPTs) following adjuvant therapy for resected stages II and IIIa non-small cell lung cancer (NSCLC) was investigated. Data regarding SPTs were prospectively collected in all patients accrued to Eastern Cooperative Group Oncology E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC). Four hundred eighty-eight patients were accrued to the study, 242 to the RT arm and 246 to the CRT arm. Median follow-up was 73 months. Thirty patients (6.1%) developed 33 SPTs, 20 in the RT arm and ten in the CRT arm. Ten SPTs occurred within the upper aerodigestive tract, six in the RT arm and four in the CRT arm. Twenty-three SPTs occurred in other organs, 17 in the RT arm and six in the CRT arm. Median time to detection of a SPT for those patients randomized to RT and CRT was 43 and 36 months, respectively. The incidence of SPTs was 1.8% per patient-year of follow-up. Excluding skin tumors, the relative risk of death following diagnosis of a SPT for patients randomized to the CRT arm as compared with those randomized to RT alone was 2.26 (95% confidence interval, 0.78-5.58, P=0.12). Patients are at risk for developing a SPT following resection of stages II and IIIa NSCLC. The majority of SPTs occur outside the aerodigestive tract. Following development of a non-skin SPT, the survival difference between patients who had received adjuvant CRT and those treated with adjuvant RT alone was not significant.

KW - Adjuvant therapy

KW - Non-small cell lung cancer

KW - Resectable

KW - Second primary tumors

UR - http://www.scopus.com/inward/record.url?scp=10744231701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744231701&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(03)00274-5

DO - 10.1016/S0169-5002(03)00274-5

M3 - Article

VL - 42

SP - 79

EP - 86

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -